Clinical Trial

A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, multi-center, phase III clinical trial designed to evaluate the efficacy of XNW5004 tablets versus Chidamide in Relapsed/Refractory PTCL, with a target of enrolling 120 subjects.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-10.
Status change: Not Yet Recruiting → Recruiting 2026-01-07
Trial Details
NCT Number NCT06776952
Lead Sponsor Evopoint Biosciences Inc.
Conditions Relapsed/Refractory Peripheral T Cell Lymphoma
Enrollment 120 participants
Start Date 2025-04-10
Primary Completion 2028-01 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-09